Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide

Blood - Tập 98 Số 12 - Trang 3456-3464 - 2001
Leo Luznik1, Sanju Jalla1, Laura Engstrom1, Robert Iannone1, Ephraim J. Fuchs1
1From the Divisions of Hematopoiesis/Immunology, Hematologic Malignancies, and Pediatric Oncology, Johns Hopkins Oncology Center, Baltimore, MD.

Tóm tắt

AbstractTreatment of leukemia by myeloablative conditioning and transplantation of major histocompatibility complex (MHC)–mismatched stem cells is generally avoided because of the high risk of graft rejection or lethal graft-versus-host disease (GVHD). This study shows that MHC-incompatible cells can engraft stably after nonmyeloablative conditioning with immunosuppressive chemotherapy and low-dose total body irradiation (TBI). Long-term mixed hematopoietic chimerism, clonal deletion of donor-reactive T cells, and bidirectional cytotoxic T-cell tolerance were achieved by transplanting MHC-mismatched marrow cells into recipients conditioned with pretransplantation fludarabine or cyclophosphamide (Cy), 50 to 200 cGy TBI on day −1, and Cy 200 mg/kg intraperitoneally on day 3. In this model, long-term donor chimerism was proportional to the dose of TBI or donor marrow cells. Pretransplantation fludarabine and posttransplantation Cy were both required for alloengraftment, but the drugs had additional effects. For example, fludarabine sensitized host stem cells to the toxicity of TBI, because animals conditioned with both agents had higher chimerism than animals conditioned with TBI alone (P < .05). Also, posttransplantation Cy attenuated lethal and nonlethal GVH reactions, because F1 recipients of host-reactive, parental spleen cells survived longer (P < .05) and had lower donor cell chimerism (P < .01) if they received posttransplantation Cy than if they did not. Finally, delayed infusions of donor lymphocytes into mixed chimeras prolonged survival after leukemia challenge (P < .0001) without causing lethal GVHD. These results indicate that stable engraftment of MHC-incompatible cells can be induced after fludarabine-based, nonmyeloablative conditioning and that it serves as a platform for adoptive immunotherapy with donor lymphocyte infusions.

Từ khóa


Tài liệu tham khảo

Thomas, 1999, Hematopoietic cell transplantation.

Henslee-Downey, 1997, Use of partially mismatched related donors extends access to allogeneic marrow transplant., Blood., 89, 3864, 10.1182/blood.V89.10.3864

Ash, 1991, Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion., Bone Marrow Transplant., 7, 443

Anasetti, 1989, Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma., N Engl J Med., 320, 197, 10.1056/NEJM198901263200401

Aversa, 1999, Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia., J Clin Oncol., 17, 1545, 10.1200/JCO.1999.17.5.1545

Guinan, 1999, Transplantation of anergic histoincompatible bone marrow allografts., N Engl J Med., 340, 1704, 10.1056/NEJM199906033402202

Truitt, 1991, Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation., Blood., 77, 2515, 10.1182/blood.V77.11.2515.2515

Clift, 1990, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens., Blood., 76, 1867, 10.1182/blood.V76.9.1867.1867

Leong, 1992, Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression., Eur J Immunol., 22, 2825, 10.1002/eji.1830221111

Tomita, 1994, Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen., J Immunol., 153, 1087, 10.4049/jimmunol.153.3.1087

de Vries-van der Zwan, 1997, Specific tolerance induction and transplantation: a single-day protocol., Blood., 89, 2596, 10.1182/blood.V89.7.2596

Colson, 1996, Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach., J Immunol., 157, 2820, 10.4049/jimmunol.157.7.2820

Wekerle, 1998, Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance., J Exp Med., 187, 2037, 10.1084/jem.187.12.2037

Sykes, 1999, Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation., Lancet., 353, 1755, 10.1016/S0140-6736(98)11135-2

Bunn, 1996, The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man., Clin Nephrol., 45, 29

Enright, 1993, Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy., Transplantation., 55, 1339, 10.1097/00007890-199306000-00024

Tollemar, 1989, Variables predicting deep fungal infections in bone marrow transplant recipients., Bone Marrow Transplant., 4, 635

Curtis, 1999, Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study., Blood., 94, 2208

Chun, 1991, Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies., J Clin Oncol., 9, 175, 10.1200/JCO.1991.9.1.175

Cheson, 1995, Infectious and immunosuppressive complications of purine analog therapy., J Clin Oncol., 13, 2431, 10.1200/JCO.1995.13.9.2431

Frank, 1999, Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling., Nat Med., 5, 444, 10.1038/7445

Giralt, 1997, Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy., Blood., 89, 4531, 10.1182/blood.V89.12.4531

Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases., Blood., 91, 756, 10.1182/blood.V91.3.756

Khouri, 1998, Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies., J Clin Oncol., 16, 2817, 10.1200/JCO.1998.16.8.2817

Childs, 1999, Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses., Blood., 94, 3234, 10.1182/blood.V94.9.3234

Fuchs, 1992, B cells turn off virgin but not memory T cells., Science., 258, 1156, 10.1126/science.1439825

Colson, 1995, A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers., J Immunol., 155, 4179, 10.4049/jimmunol.155.9.4179

Matsuzaki, 1990, Clonal deletion of self-reactive T cells at the early stage of T cell development in thymus of radiation bone marrow chimeras., J Immunol., 145, 46, 10.4049/jimmunol.145.1.46

Ramsdell, 1989, A nondeletional mechanism of thymic self tolerance., Science., 246, 1038, 10.1126/science.2511629

Tutschka, 1981, Suppressor cells in transplantation tolerance, I: suppressor cells in the mechanism of tolerance in radiation chimeras., Transplantation., 32, 203, 10.1097/00007890-198109000-00005

Ryan, 1991, Allostimulatory analysis of a newly-defined and widely-distributed Mls superantigen., Immunogenetics., 34, 88, 10.1007/BF00211421

Abe, 1991, Characterization of a new minor lymphocyte stimulatory system. I. Cluster of self antigens recognized by “I-E-reactive” Vβs, Vβ5, Vβ11, and Vβ12 T cell receptors for antigen., J Immunol., 147, 739, 10.4049/jimmunol.147.3.739

Mayumi, 1986, Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients., Transplantation., 42, 417, 10.1097/00007890-198610000-00018

Via, 1987, Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs.-host disease., J Immunol., 139, 1840, 10.4049/jimmunol.139.6.1840

Sykes, 1988, Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells., J Exp Med., 168, 2391, 10.1084/jem.168.6.2391

Pelot, 1999, Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen., Biol Blood Marrow Transplant., 5, 133, 10.1053/bbmt.1999.v5.pm10392959

Johnson, 1993, Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease., Bone Marrow Transplant., 11, 329

Johnson, 1995, Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease., Blood., 85, 3302, 10.1182/blood.V85.11.3302.bloodjournal85113302

Blazar, 1997, CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells., J Immunol., 159, 3460, 10.4049/jimmunol.159.7.3460

Petersdorf, 1999, Effect of HLA mismatches on the outcome of hematopoietic transplants., Curr Opin Immunol., 11, 521, 10.1016/S0952-7915(99)00016-3

Spitzer, 2000, Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies., Biol Blood Marrow Transplant., 6, 309, 10.1016/S1083-8791(00)70056-5

Ildstad, 1986, Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2?B10)., J Immunol., 136, 28, 10.4049/jimmunol.136.1.28

Ildstad, 1985, Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance., J Exp Med., 162, 231, 10.1084/jem.162.1.231

Sullivan, 1989, Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms., N Engl J Med., 320, 828, 10.1056/NEJM198903303201303

Tomita, 2000, Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide., J Immunol., 165, 34, 10.4049/jimmunol.165.1.34

Plunkett, 1991, Metabolism and action of purine nucleoside analogs., Pharmacol Ther., 49, 239, 10.1016/0163-7258(91)90057-S

Petrus, 2000, An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD., Biol Blood Marrow Transplant., 6, 182, 10.1016/S1083-8791(00)70041-3

Gregoire, 1994, Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation., Int J Radiat Oncol Biol Phys., 30, 363, 10.1016/0360-3016(94)90016-7

Gregoire, 1994, Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine., Cancer Res., 54, 468

de Vries-van der Zwan, 1998, An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers., Transpl Immunol., 6, 147, 10.1016/S0966-3274(98)80039-7

Sykes, 1997, Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning., Nat Med., 3, 783, 10.1038/nm0797-783

Mayumi, 1989, Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide., J Exp Med., 169, 213, 10.1084/jem.169.1.213

Eto, 1990, Intrathymic clonal deletion of Vβ6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens., J Exp Med., 171, 97, 10.1084/jem.171.1.97

Uharek, 1992, Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation., Blood., 79, 1612, 10.1182/blood.V79.6.1612.1612

Kolb, 1995, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia., Blood., 86, 2041, 10.1182/blood.V86.5.2041.bloodjournal8652041

Collins, 1997, Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation., J Clin Oncol., 15, 433, 10.1200/JCO.1997.15.2.433

Johnson, 1993, Delayed infusion of normal donor cells after MHC matched bone marrow transplantation provides an antileukemic reaction without graft versus host disease., Bone Marrow Transpl., 11, 329

Antin, 1992, Cytokine dysregulation and acute graft-versus-host disease., Blood., 80, 2964, 10.1182/blood.V80.12.2964.2964

Johnson, 1999, Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy., J Immunol., 163, 6479, 10.4049/jimmunol.163.12.6479

Thông tin
Thông tin xuất bản

Blood

Tập 98 Số 12

3456-3464

Thông tin tác giả